Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,427 full-time employees. The company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.
¿Quién es el CEO de Integra Lifesciences Holdings Corp?
Ms. Mojdeh Poul es el President de Integra Lifesciences Holdings Corp, se unió a la empresa desde 2025.
¿Qué tal es el rendimiento del precio de la acción IART?
El precio actual de IART es de $13.6, ha disminuido un 2.29% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Integra Lifesciences Holdings Corp?
Integra Lifesciences Holdings Corp pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Integra Lifesciences Holdings Corp?
La capitalización bursátil actual de Integra Lifesciences Holdings Corp es $1.0B
¿Es Integra Lifesciences Holdings Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 9 analistas han realizado calificaciones de análisis para Integra Lifesciences Holdings Corp, incluyendo 2 fuerte compra, 1 compra, 8 mantener, 4 venta, y 2 fuerte venta